Rocuronium 0.6 mg/kg intubating dose + Rocuronium 0.9 mg/kg intubating dose + Rocuronium 0.1 mg/kg maintenance dose + Rocuronium 0.15 mg/kg maintenance dose + Rocuronium 0.2 mg/kg maintenance + Vecuronium 0.1 mg/kg intubating dose + Vecuronium 0.025 mg/kg maintenance dose

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anesthesia

Conditions

Anesthesia

Trial Timeline

Feb 1, 2003 → Feb 1, 2004

About Rocuronium 0.6 mg/kg intubating dose + Rocuronium 0.9 mg/kg intubating dose + Rocuronium 0.1 mg/kg maintenance dose + Rocuronium 0.15 mg/kg maintenance dose + Rocuronium 0.2 mg/kg maintenance + Vecuronium 0.1 mg/kg intubating dose + Vecuronium 0.025 mg/kg maintenance dose

Rocuronium 0.6 mg/kg intubating dose + Rocuronium 0.9 mg/kg intubating dose + Rocuronium 0.1 mg/kg maintenance dose + Rocuronium 0.15 mg/kg maintenance dose + Rocuronium 0.2 mg/kg maintenance + Vecuronium 0.1 mg/kg intubating dose + Vecuronium 0.025 mg/kg maintenance dose is a phase 3 stage product being developed by Merck for Anesthesia. The current trial status is completed. This product is registered under clinical trial identifier NCT00970762. Target conditions include Anesthesia.

What happened to similar drugs?

1 of 20 similar drugs in Anesthesia were approved

Approved (1) Terminated (0) Active (19)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00970762Phase 3Completed